Literature DB >> 26448040

Is there treatment for traumatic optic neuropathy?

Benjamin C Chaon1, Michael S Lee.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to discuss current controversies surrounding the proposed treatments for traumatic optic neuropathy (TON) and review recent evidence from the literature relating to these therapeutic options. RECENT
FINDINGS: No recent randomized controlled trials investigating surgical or medical interventions for TON exist. The current literature regarding treatment of TON consists mainly of small, mostly retrospective, observational studies. Treatment of TON with corticosteroids, surgical decompression of the optic canal or combinations of surgery and corticosteroids does not appear to offer improved visual outcomes compared with observation alone. Recent evidence suggests that there may be diminished functional reserve of the optic nerve following trauma. Novel neuroprotective therapies, such as erythropoietin, are currently under investigation in the treatment of TON.
SUMMARY: TON may lead to profound visual disability. Because of the absence of Class I evidence relating to treatment of TON, a lack of consensus exists among clinicians regarding the appropriate treatment for TON. Our review of the recent literature finds that there is still no reliable evidence that treatment of TON with corticosteroids, surgical optic canal decompression or both confers any benefit over observation alone, and yet these interventions incur an additional risk that may not warrant their routine use.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26448040     DOI: 10.1097/ICU.0000000000000198

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  16 in total

1.  Combination analysis on the impact of the initial vision and surgical time for the prognosis of indirect traumatic optic neuropathy after endoscopic transnasal optic canal decompression.

Authors:  Wei Yan; Jingquan Lin; Wanglu Hu; Qun Wu; Jianmin Zhang
Journal:  Neurosurg Rev       Date:  2020-02-25       Impact factor: 3.042

2.  High-Mobility Group Box 1 Inhibitor BoxA Alleviates Neuroinflammation-Induced Retinal Ganglion Cell Damage in Traumatic Optic Neuropathy.

Authors:  Jingyi Peng; Jiayi Jin; Wenru Su; Wanwen Shao; Weihua Li; Zhiquan Li; Huan Yu; Yongxin Zheng; Liuxueying Zhong
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

3.  Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.

Authors:  Brian C Tse; Galina Dvoriantchikova; Wensi Tao; Ryan A Gallo; John Y Lee; Dmitry Ivanov; David T Tse; Daniel Pelaez
Journal:  Exp Eye Res       Date:  2020-08-03       Impact factor: 3.467

Review 4.  An evolving perspective of endoscopic transnasal optic canal decompression for traumatic optic neuropathy in clinic.

Authors:  Jingquan Lin; Wanglu Hu; Qun Wu; Jianmin Zhang; Wei Yan
Journal:  Neurosurg Rev       Date:  2019-11-22       Impact factor: 3.042

5.  Reactive Fibroblasts in Response to Optic Nerve Crush Injury.

Authors:  Xiangxiang Liu; Yuan Liu; Huiyi Jin; Mohamed M Khodeiry; Weizheng Kong; Ningli Wang; Jae K Lee; Richard K Lee
Journal:  Mol Neurobiol       Date:  2020-11-12       Impact factor: 5.590

6.  Remote Ischemic Post-Conditioning Therapy is Protective in Mouse Model of Traumatic Optic Neuropathy.

Authors:  Muhammad Nadeem; Adam Kindelin; Laura Mahady; Kanchan Bhatia; Md Nasrul Hoda; Andrew F Ducruet; Saif Ahmad
Journal:  Neuromolecular Med       Date:  2020-11-13       Impact factor: 3.843

Review 7.  Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials.

Authors:  Sonia Labrador-Velandia; María Luz Alonso-Alonso; Sara Alvarez-Sanchez; Jorge González-Zamora; Irene Carretero-Barrio; José Carlos Pastor; Iván Fernandez-Bueno; Girish Kumar Srivastava
Journal:  World J Stem Cells       Date:  2016-11-26       Impact factor: 5.326

8.  A Novel Mouse Model of Traumatic Optic Neuropathy Using External Ultrasound Energy to Achieve Focal, Indirect Optic Nerve Injury.

Authors:  Wensi Tao; Galina Dvoriantchikova; Brian C Tse; Steven Pappas; Tsung-Han Chou; Manuel Tapia; Vittorio Porciatti; Dmitry Ivanov; David T Tse; Daniel Pelaez
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

9.  APP upregulation contributes to retinal ganglion cell degeneration via JNK3.

Authors:  Chao Liu; Cheng-Wu Zhang; Yi Zhou; Wan Qing Wong; Liying Corinne Lee; Wei Yi Ong; Sung Ok Yoon; Wanjin Hong; Xin-Yuan Fu; Tuck Wah Soong; Edward H Koo; Lawrence W Stanton; Kah-Leong Lim; Zhi-Cheng Xiao; Gavin S Dawe
Journal:  Cell Death Differ       Date:  2017-12-13       Impact factor: 15.828

10.  Tumor Necrosis Factor Inhibition in the Acute Management of Traumatic Optic Neuropathy.

Authors:  Brian C Tse; Galina Dvoriantchikova; Wensi Tao; Ryan A Gallo; John Y Lee; Steven Pappas; Roberta Brambilla; Dmitry Ivanov; David T Tse; Daniel Pelaez
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.